(function(){ var content_array=["

关于龙沙<\/p> \n

龙沙是全球制药、生物技术与营养市场的优秀合作伙伴。我们致力于助力客户推出创新药物辅助治疗一系列的疾病，成就更健康的世界。为达成这一使命，我们将先进生产制造、科学专业技术、卓越工艺及技术洞察力完美结合。我们全方位的产品与服务帮助客户在医疗保健行业的发现与创新成果实现商业化。<\/p> \n

1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区。发展至今，业务已遍及全球五大洲。我们拥有约16,000名全职员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2021年，公司销售额达54亿瑞士法郎，核心业务的息税折旧摊销前利润（EBITDA）达17亿瑞士法郎。更多详情，请访问 www.lonza.com<\/a>；或关注公众号“龙沙制药与生物技术”。<\/p> \n

关于绿竹<\/b><\/p> \n

北京绿竹生物技术股份有限公司（绿竹生物）成立于2001年11月，致力于在人类医学领域取得卓越成就。绿竹生物专注研发用于预防、控制和治疗人类疾病的疫苗和治疗性双特异性抗体，拥有一支强大的研发团队，利用先进一流的技术开发和生产满足临床需求的各类生物制品。 <\/p> \n

绿竹生物成立后的首个10年内，成功研发出了3种多糖蛋白结合疫苗、2种多糖疫苗和1种病毒灭活疫苗，此6种疫苗产品均转让给了北京智飞绿竹生物制药有限公司。公司自2009年开始进行人用单克隆抗体、双特异性抗体药物、重组病毒疫苗的研究，之后陆续获得了相应候选药物的临床批件。公司将充分利用已经建立的定向抗原呈递技术开发多种病毒性疫苗，同时利用自主开发的双功能抗体平台技术（注册商标Fabite^{®<\/sup>），开发多种用于人类血液系统恶性肿瘤治疗用的双特异性抗体药物。<\/p> \n}

Additional Information and Disclaimer<\/p> \n

Lonza Group Ltd has its headquarters in Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.<\/p> \n

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking state-ments included in this news release due to various factors. Furthermore, except as otherwise re-quired by law, Lonza Group Ltd disclaims any intention or obligation to update the statements con-tained in this news release.<\/p>"]; $("#dvExtra").html(content_array[0]);})();